FDA Approves Fall 2026 COVID Shots, Keeps Narrow Use

FDA approved updated, XFG-adapted 2026–2027 formula COVID-19 vaccines from all three US manufacturers over a 48-hour span: Pfizer-BioNTech’s Comirnaty XFG and Moderna’s Spikevax and mNEXSPIKE on 27 August, and Novavax’s Nuvaxovid on 27–28 August, the latter also clearing EU and Japanese authorization in the same window. Each is a strain-change supplement, not a new product review — and each carries forward, unchanged, the restricted indication FDA first adopted a year ago rather than reopening the shots to the general population.

Three sponsors, one filing type

All three approvals are supplemental Biologics License Applications — the mechanism FDA has used every year since the annual strain-update cycle began, and the same route that carried the 2025-2026 formulas through. A sBLA lets a sponsor update an already-licensed vaccine to track a new circulating variant using chemistry, manufacturing, and control data plus supporting immunogenicity data, without running a fresh clinical efficacy trial for each seasonal change. For 2026-2027, FDA aligned all three sponsors on the same target: the XFG variant, part of the JN.1 lineage, per the strain composition it recommended earlier in the year for US COVID-19 vaccines beginning fall 2026.

The indication that didn't move

The operationally significant fact in this cycle is what stayed the same. FDA narrowed COVID-19 vaccine eligibility for the 2025-2026 season, moving away from the broad, all-ages availability of earlier cycles to a risk-based framework: routine coverage for adults 65 and older, and for younger people only if they carry at least one underlying condition that raises their risk of severe disease. The 2026-2027 approvals repeat that same structure product for product, rather than reopening the shots to a general-population indication. For regulatory and medical-affairs teams, that continuity matters as much as a change would: promotional claims, patient-facing eligibility messaging, and payer coverage criteria built around last season's label do not need to be rebuilt from scratch, but they cannot default back to pre-2025 all-ages language either.

Where the three products don't quite match

• Comirnaty XFG (Pfizer-BioNTech): adults 65 and older, or ages 5 through 64 with at least one underlying condition that increases the risk of severe COVID-19.
• Spikevax (Moderna): adults 65 and older, or ages 6 months through 64 with a qualifying underlying condition — the only one of the four products reaching into the under-5 population.
• mNEXSPIKE (Moderna): adults 65 and older, or ages 12 through 64 with a qualifying underlying condition. Its age floor sits above Spikevax's, so the two Moderna products are not interchangeable across the full pediatric range.
• Nuvaxovid (Novavax/Sanofi), US indication: adults 65 and older, or ages 12 through 64 with a qualifying underlying condition — a narrower age structure than the EU and Japanese approvals granted in the same announcement window, which is worth checking separately for multinational labeling.